Expression Profiles and Bioinformatic Analysis of Circular RNAs in Db/Db Mice with Cardiac Fibrosis
Lingling Yuan,Ting Wang,Jinsheng Duan,Jing Zhou,Na Li,Guizhi Li,Hong Zhou
DOI: https://doi.org/10.2147/dmso.s465588
2024-05-23
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Lingling Yuan, 1 Ting Wang, 1 Jinsheng Duan, 2 Jing Zhou, 1 Na Li, 1 Guizhi Li, 1 Hong Zhou 1 1 Department of Endocrinology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050004, People's Republic of China; 2 Department of Cardiology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050004, People's Republic of China Correspondence: Hong Zhou, Department of Endocrinology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China, Tel +86-15130119625, Email ; Introduction: Cardiac fibrosis is one of the important causes of heart failure and death in diabetic cardiomyopathy (DCM) patients. Circular RNAs (circRNAs) are covalently closed RNA molecules in eukaryotes and have high stability. Their role in myocardial fibrosis with diabetic cardiomyopathy (DCM) remain to be fully elucidated. This study aimed to understand the expression profiles of circRNAs in myocardial fibrosis with DCM, exploring the possible biomarkers and therapeutic targets for DCM. Methods: At 21 weeks of age, db/db mice established the type 2 DCM model measured by echocardiography, and the cardiac tissue was extracted for Hematoxylin–eosin, Masson's trichrome staining, and transmission electron microscopy. Subsequently, the expression profile of circRNAs in myocardial fibrosis of db/db mice was constructed using microarray hybridization and verified by real‐time quantitative polymerase chain reaction. A circRNA–microRNA–messenger RNA coexpression network was constructed, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis were done. Results: Compared with normal control mice, db/db mice had 77 upregulated circRNAs and 135 downregulated circRNAs in their chromosomes (fold change ≥ 1.5, P ≤ 0.05). Moreover, the enrichment analysis of circRNA host genes showed that these differentially expressed circRNAs were mainly involved in mitogen-activated protein kinase signaling pathways. CircPHF20L1, circCLASP1, and circSLC8A1 were the key circRNAs. Moreover, circCLASP1/miR-182-5p/Wnt7a, circSLC8A1/miR-29b-1-5p/Col12a1, and most especially circPHF20L1/miR-29a-3p/Col6a2 might be three novel axes in the development of myocardial fibrosis in DCM. Conclusion: The findings will provide some novel circRNAs and molecular pathways for the prevention or clinical treatment of DCM through intervention with specific circRNAs. Keywords: Circular RNAs, expression profile, diabetic cardiomyopathy, cardiac fibrosis, bioinformatic analysis Circular RNAs (circRNAs) are covalently closed RNA molecules in eukaryotes that have high stability; compared with linear RNAs, they are more resistant to exonucleases. 1 CircRNAs mainly act as microRNA (miRNA) sponges, protecting target messenger RNAs from miRNA-dependent degradation; therefore, the target RNA is more actively translated and bound by ribosomes. 2 In patients with diabetes, diabetic cardiomyopathy (DCM) is a specific cardiovascular complication that first manifests as diastolic dysfunction and eventually progresses to refractory heart failure. Myocardial fibrosis is a critical pathological feature of DCM. 3 However, the mechanism involved in the development of myocardial fibrosis in DCM remains unclear. CircRNAs have been reported to play an important role in myocardial fibrosis in DCM. 4–6 A recent study found that diabetes-induced circulation-associated circRNA (DICAR) was downregulated in diabetic mouse hearts and was associated with a negative fibrosis index in DICAR-deficient mice. 7 Tang et al determined that circ_000203 was upregulated in the myocardium from mouse models of type 2 diabetes mellitus (T2DM) and increased the expression of colla2, colla3, and α-smooth muscle actin in cardiac fibroblasts (CFs), thereby exacerbating myocardial fibrosis. 4 In another study, circRNA_010567 was increased in the myocardium from T2DM mice, and knockdown of this circRNA remarkably suppressed myocardial fibrosis via the miR-141/TGF-b1 pathway in angiotensin II (AngII)-induced CFs. 5 CircHIPK3 was found to be upregulated in mouse DCM models induced by streptozotocin, and knockdown of this circRNA could ameliorate myocardial fibrosis and cardiac function in vivo and decrease CF proliferation induced by Ang II via the miR-29b-3p/Col1a1-Col3a1 pathway in vitro. 6 Unfortunately, this study did not perform echocardiography on db/db mice and used Ang II to induce fibroblast fibrosis instead of high glucose (HG), which may not fully reflect the pathogenesis of myocardial fibrosis in HG conditions. Recently, three studies have analyzed the competitive endogenou -Abstract Truncated-
endocrinology & metabolism